Flow cytometry analysis of the tumor microenvironment and spleen 2 days after the last treatment revealed that adv did not significantly affect innate immune cells, including NK cells, activated NK cells (CD69+ and CD11b+ CD27+), activated dendritic cells (DCs) (major histocompatibility complex [MHC] II+), “M1-like” macrophages (M1) (CD86+), “M2-like” macrophages (M2) (CD206+), or other immune clusters (Figures 1B and 1E). The gene discussed is CD86; the disease is neoplasm.